The company said that the decline in revenues reflected lower industry-wide reimbursement rates under PAMA.
The proceeds from the sale will go toward the planned acquisition of Curetis and to support the ongoing submission of its technology to US regulators.
The bank believes investors are too focused on the potential of PacBio's merger with Illumina falling through rather than recent developments regarding its technology.
Users can apply both companies' tools to view genomic evidence linked to disease mutations, reducing the time needed to examine a variant's pathogenicity.
PetaGene is expanding further into South Asia and other regions by naming Dubai-based Alliance Global as its exclusive partner in several countries.
The buccal epithelial cell-based epigenetic clock corresponded with age in those under 20, but skewed slightly higher in a small subset of children with autism spectrum disorder.
The project will provide approved researchers with access to samples and deidentified data collected from volunteer patients with Duchenne muscular dystrophy.
With the certification, the Silicon Valley-based company aims to roll out its AvaGen test for keratoconus and corneal dystrophies beginning this quarter.
The Voyage study is designed to enroll more than 150,000 people and will follow participants for at least seven years.
Last week, GenomeWeb's readers were most interested in announcement from Qiagen that it has partnered with Illumina to develop NGS-based IVD kits.
The companies will develop an assay to guide treatment with a type of radiopharmaceutical therapy in patients with these rare tumors.
The company said the revenue growth was driven by growing international demand for its noninvasive prenatal testing products and services.
Investigators at the Foundation for Research and Technology - Hellas, a Greek research institute, are coordinating the effort.
Thousands of parent-child exomes helped researchers identify apparently causative mobile element insertions in a handful of children with developmental disorders.
The test, TruGraf, assesses differentially expressed genes in blood to rule out subclinical kidney transplant rejection in patients with stable renal function.
The single-cell genomics firm will collaborate with Fred Hutchinson Cancer Research Center on a targeted sequencing panel for MRD monitoring in AML.
The decision, which enables Medicare reimbursement, is effective for tests administered on or after Dec. 1.
The companies are collaborating to return actionable genetic information to all participants of the Project Baseline Health Study.
Researchers analyzed data from 23andMe and the UK Biobank to find that errors of recombination, like uniparental disomy, can be present among healthy individuals.
The startup has developed a platform that allows precise engineering of optical properties to provide high-resolution analysis of single cells by high throughput flow cytometry.
A new study in Science used allele-specific expression data to find candidate genes that may have contributed to mendelian muscle disease in patients.
Using ancient DNA profiling, isotope analyses, and archeological clues, investigators saw high-status, male-centered families, along with more modest graves for unrelated individuals.
A South African university has told the Wellcome Sanger Institute to return DNA samples it has from indigenous African communities, The Times reports.
The University of California, Berkeley's Rasmus Nielsen and Xinzhu Wei have retracted their CCR5 gene paper due to a technical artifact.
University of Virginia researchers are exploring a genetic risk test to gauge type 1 diabetes risk, NPR reports.
In PNAS this week: researchers compare two high-grade neuroendocrine lung cancers, height among ancient Europeans, and more.